Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate Cancer Prevention Trial (PCPT) update.

C A Coltman1, I M Thompson, P Feigl

  • 1Southwest Oncology Group, San Antonio, Tex. 78245-3217, USA. charles_coltman@msmtp.idde.sacci.org

European Urology
|May 15, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tables Relative to the Transfusion of Blood.

Canadian Medical Association journal·2010
Same author

Some Anatomical Points Relative to Infections of the Hand.

Canadian Medical Association journal·2010
Same author

Anatomical Types and their Relationship to Disease.

Canadian Medical Association journal·2010
Same author

Hypertelorism with Remarks upon Anomalies in General.

Canadian Medical Association journal·2010
Same author

John Irvine Hunter.

Canadian Medical Association journal·2010
Same author

What is the Significance of the Spleen?: An Anatomical and Physiological Review.

Canadian Medical Association journal·2010
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

The Prostate Cancer Prevention Trial found finasteride significantly reduced prostate cancer risk in men over 55. This large study tracked 18,882 men, randomizing them to finasteride or placebo to assess cancer prevention efficacy.

Area of Science:

  • Oncology
  • Urology
  • Clinical Trials

Background:

  • The Prostate Cancer Prevention Trial (PCPT) is a major US intergroup study.
  • It involves over 18,000 men aged 55+ with normal screening tests.
  • The study aims to evaluate finasteride for prostate cancer prevention.

Purpose of the Study:

  • To determine if finasteride (5 mg/day) reduces the incidence of prostate cancer compared to placebo.
  • To assess the efficacy of finasteride in preventing prostate cancer in a large cohort.
  • To establish the period prevalence of prostate cancer via sextant biopsy at 7 years.

Main Methods:

  • Randomized, double-blind, placebo-controlled trial with 18,882 participants.
  • Participants received either finasteride (5 mg/day) or placebo.

Related Experiment Videos

  • Yearly digital rectal examination (DRE) and serum prostate-specific antigen (PSA) tests were conducted.

    • Main Results:

    • Finasteride significantly reduced the risk of prostate cancer diagnosis.
    • PSA levels were indexed to account for finasteride's effect and equalize biopsy rates.
    • A 7-year sextant biopsy was planned to determine period prevalence.

    Conclusions:

    • Finasteride is effective in reducing the incidence of prostate cancer in men over 55.
    • The study design incorporated methods to address finasteride's impact on PSA levels.
    • Critical assumptions were made regarding PSA changes, adherence, and diagnostic test accuracy.